"The NeuroCognitive Institute (NCI) was established in 1994 and initially named the NeuroRehab Institute. Since this92242385 time, we have remained committed to our scientist-practitioner model upon which the institute was founded. This model requires that our doctors remain actively involved in research but from within a private practice setting. This gives our patients the exposure to recent and ongoing developments within the clinical neurosciences without the bureaucracy and interpersonal alienation often experienced at larger academic institutions. Over the past two decades, we have become one of the premiere centers in New Jersey for the diagnosis and treatment of cognitive and related neurobehavioral and neuropsychiatric disorders."

During the past decade, The NeuroCognitive Institute conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 7 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The NeuroCognitive Institute" #1 sponsor was "Genentech, Inc." with 4 trials, followed by "Otsuka Pharmaceutical Development & Commercialization, Inc." with 3 trials sponsored, "ACADIA Pharmaceuticals Inc." with 2 trials sponsored, "Emalex Biosciences Inc." with 2 trials sponsored and "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The NeuroCognitive Institute" #1 collaborator was "Pfizer" with 2 trials as a collaborator, "APCER Life Sciences" with 1 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Grifols Biologicals, LLC" with 1 trials as a collaborator and "ICON Clinical Research" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "The NeuroCognitive Institute" are "Alzheimer's Disease" (11 trials), "Alzheimer Disease" (2 trials), "Mild Cognitive Impairment" (2 trials), "Neuropsychiatric Symptoms Related to Neurodegenerative Disease" (2 trials) and "Agitation in Participants With Dementia of the Alzheimer's Type" (1 trials). Many other conditions were trialed in "The NeuroCognitive Institute" in a lesser frequency.

Most popular intervention types in "The NeuroCognitive Institute" are "Drug" (21 trials), "Other" (2 trials), "Biological" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Bapineuzumab 0.5 mg/kg" (2 trials), "Bapineuzumab 1.0 m/kg" (2 trials), "Ecopipam" (2 trials) and "Pimavanserin" (2 trials). Other intervention names were less common.

The vast majority of trials in "The NeuroCognitive Institute" are 23 trials for "All" genders.

Currently, there are NaN active trials in "The NeuroCognitive Institute". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in The NeuroCognitive Institute, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in The NeuroCognitive Institute, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".